Pluri Inc. develops cell-based technologies built around its proprietary 3D cell expansion platform. Company news commonly covers mass-scale cell expansion, biofarming, regenerative medicine applications, immune-cell manufacturing intellectual property, and the use of PluriCDMO™ for contract development and manufacturing programs involving cell-derived therapeutics, biologics, and placenta-derived biomaterials.
Recurring updates also address Pluri’s venture and subsidiary activity across foodtech, agtech, and health and aesthetics, including Coffeesai, Ever After Foods, Kokomodo, and Cellav. Additional news themes include commercial collaborations, patent grants, board and governance changes, private placements, and other capital actions tied to Pluri’s platform, subsidiaries, and public-company structure.
Pluri (PLUR) will host online investor conference sessions on October 29, 2026, to provide updates on company developments. CEO and President Yaky Yanay and Chairman and Active Investor Alejandro Weinstein will participate via Zoom. The Hebrew-language session starts at 11:00 a.m. Israel Time, and the English-language session starts at 8:30 a.m. Eastern Time.
Pluri (PLUR) signed a definitive partnership agreement with ZEO ScientifiX to expand their U.S. regenerative medicine manufacturing and commercial platform. Pluri will grant defined manufacturing technology and know-how rights while retaining ownership of its underlying technology and intellectual property. In exchange, ZEO will initially issue common shares representing 50% of its outstanding common stock immediately following closing.
The agreement provides exclusive U.S. rights to Pluri’s Cellav aesthetic product line, including future offerings. The companies intend to broaden offerings through ZEO’s existing physician network and commercial infrastructure, subject to applicable regulatory requirements. Closing is expected in the fourth quarter of 2026, subject to ancillary agreements, certain approvals and delivery of valuations. Neither company requires stockholder approval.
Pluri (Nasdaq, TASE: PLUR) announced an agreement for Chairman and largest shareholder Alejandro Weinstein to acquire its European Investment Bank loan.
Upon completion, Weinstein will replace the EIB as lender and assume its existing rights and remedies. The loan will remain outstanding; Pluri will have no further financial or repayment obligations to the EIB, but the debt itself will not be extinguished. Pluri and Weinstein intend to negotiate revised loan terms within a reasonable period and present a proposed long-term resolution plan. Pluri views the assignment as a step toward a more flexible financing framework supporting commercialization. The proposed assignment received approval from a special independent board committee and the board, including a majority of independent directors. Completion and revised loan terms remain pending.
Ever After Foods and Roslin Technologies reported higher cultivated meat productivity in their joint production program compared with a stirred-tank suspension benchmark. The combined platform achieved 40gr/L cultivated protein, 57gr/L dry biomass and 326gr/L wet biomass. Protein and dry biomass productivity were each 19 times higher, while wet biomass productivity was 11 times higher than the same cells grown in the benchmark.
Cell density exceeded 150 million cells/ml. The results reflected 5 times higher cell density and 4 times more protein and dry biomass per cell. Structured tissue grew directly on an edible plant-based scaffold representing less than 2% of final product weight. Reported biomass and protein values excluded scaffold and media contributions. The companies are continuing development and scale-up work.
Pluri (Nasdaq: PLUR; TASE: PLUR) entered a securities purchase agreement with a single healthcare focused institutional investor for a registered direct offering of 2,228,940 Common Shares (or equivalents) at $1.50 per share, for expected gross proceeds of approximately $3.3 million before fees.
In a concurrent private placement, Pluri will issue unregistered Warrants to purchase up to 2,228,940 Common Shares, with an exercise price of $1.65, becoming exercisable six months after issuance and expiring 5.5 years later. Closing is expected on or about August 28, 2026, subject to customary conditions. According to Pluri, net proceeds will be used for working capital and general corporate purposes, and A.G.P./Alliance Global Partners is acting as sole placement agent.
Pluri (Nasdaq/TASE: PLUR) reported that its majority-owned food-tech company Ever After Foods has acquired Belgium-based Fishway BV, a biotechnology company specializing in aquatic cell biology and animal-component-free (ACF) media for the cultivated-protein industry.
The deal adds Fishway’s aquatic cell biology know-how, ACF media development capabilities and an established scientific presence in Belgium to Ever After Foods’ open, species-agnostic cultivated-protein manufacturing platform. According to Pluri, this supports Ever After Foods’ strategy to broaden its cultivated-protein applications and better support food and ingredient companies moving from development to scalable production.
In parallel with the acquisition, Ever After Foods secured an additional $2 million strategic investment through a simple agreement for future equity (SAFE) to fund ongoing platform development and commercialization activities.
Ever After Foods (NASDAQ: PLUR) announced the strategic acquisition of Fishway, following a prior technology collaboration that confirmed the compatibility of their platforms. The deal adds aquatic cell lines, animal-component-free media expertise and Fishway’s scientific team, enhancing EAF’s industrial protein manufacturing capabilities and establishing Belgium as a European center of excellence.
According to Ever After Foods, integrating Fishway’s biology and media technology with its PlantriX edible scaffold and EPB™ system is expected to shorten development cycles, reduce technical interfaces and support commercialization across multiple species, including cultivated meat, seafood and functional protein ingredients for premium pet food. In parallel, EAF secured an additional $2 million strategic investment to further expand and commercialize its platform. Additional transaction terms were not disclosed.
Pluri (Nasdaq: PLUR) announced that its consumer-health and aesthetics subsidiary, Cellav, has completed cosmetic regulatory registration and notification in the UK for its regenerative aesthetics product Regenativo+. The product is now notified on the UK Cosmetic Product Notification (UKCP) portal, enabling commercial marketing in the UK.
According to Pluri, this supports an upcoming UK launch and aligns with its strategy to expand globally in regenerative aesthetics and longevity. The company cites an estimated $900 million UK medical aesthetics market in 2026 and a European market exceeding $7.5 billion in 2025 as it advances commercial discussions with clinics, distributors, and partners.
Pluri (Nasdaq, TASE: PLUR) reported that Chairman Alejandro Weinstein has invested more than $17 million in the company over the past year, including a $1.25 million advance investment in June 2026 under an Advance Subscription Agreement. According to Pluri, Weinstein now owns more than 30% of the company’s issued and outstanding shares.
Pluri links this growing stake to its shift from platform development toward commercial execution, with an emphasis on longevity and planned U.S. commercialization. The company reports strong inbound interest from multiple U.S. parties assessing potential product purchases and technology collaborations around reproducible cell production, tailored exosomes and other biological components.
Pluri (NASDAQ: PLUR, TASE: PLUR) announced that subsidiary Cellav completed U.S. cosmetic listings for two regenerative aesthetic products, Regenativo+ and Placento+, clearing the way for a 2026 U.S. commercial launch.
The DUO-format, clinically validated formulations target the expanding U.S. medical aesthetics market, projected to reach $90 billion by 2030. Studies showed statistically significant skin and discoloration improvements with good tolerability, supporting positioning in professional regenerative aesthetics and longevity channels.